Cargando…

Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study

Venous thromboembolism (VTE) with concurrent thrombocytopenia is frequently encountered in patients with cancer. Therapeutic anticoagulation in the setting of thrombocytopenia is associated with a high risk of hemorrhage. Retrospective analyses suggest the utility of modified-dose anticoagulation in...

Descripción completa

Detalles Bibliográficos
Autores principales: Carney, Brian J., Wang, Tzu-Fei, Ren, Siyang, George, Gemlyn, Al Homssi, Amer, Gaddh, Manila, Connolly, Gregory C., Shah, Vinay I., Bogue, Thomas, Bartosic, Abigail, Neuberg, Donna, Baumann Kreuziger, Lisa, Zwicker, Jeffrey I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714719/
https://www.ncbi.nlm.nih.gov/pubmed/34662892
http://dx.doi.org/10.1182/bloodadvances.2021005966
_version_ 1784623960838635520
author Carney, Brian J.
Wang, Tzu-Fei
Ren, Siyang
George, Gemlyn
Al Homssi, Amer
Gaddh, Manila
Connolly, Gregory C.
Shah, Vinay I.
Bogue, Thomas
Bartosic, Abigail
Neuberg, Donna
Baumann Kreuziger, Lisa
Zwicker, Jeffrey I.
author_facet Carney, Brian J.
Wang, Tzu-Fei
Ren, Siyang
George, Gemlyn
Al Homssi, Amer
Gaddh, Manila
Connolly, Gregory C.
Shah, Vinay I.
Bogue, Thomas
Bartosic, Abigail
Neuberg, Donna
Baumann Kreuziger, Lisa
Zwicker, Jeffrey I.
author_sort Carney, Brian J.
collection PubMed
description Venous thromboembolism (VTE) with concurrent thrombocytopenia is frequently encountered in patients with cancer. Therapeutic anticoagulation in the setting of thrombocytopenia is associated with a high risk of hemorrhage. Retrospective analyses suggest the utility of modified-dose anticoagulation in this population. To assess the incidence of hemorrhage or thrombosis according to anticoagulation strategy, we performed a prospective, multicenter, observational study. Patients with active malignancy, acute VTE, and concurrent thrombocytopenia (platelet count <100 000/µL) were enrolled. The cumulative incidences of hemorrhage or recurrent VTE were determined considering death as a competing risk. Primary outcomes were centrally adjudicated and comparisons made according to initial treatment with full-dose or modified-dose anticoagulation. A total of 121 patients were enrolled at 6 hospitals. Seventy-five patients were initially treated with full-dose anticoagulation (62%) and 33 (27%) with modified-dose anticoagulation; 13 (11%) patients received no anticoagulation. Most patients who received modified-dose anticoagulation had a hematologic malignancy (31 of 33 [94%]) and an acute deep vein thrombosis (28 of 33 [85%]). In patients who initially received full-dose anticoagulation, the cumulative incidence of major hemorrhage at 60 days was 12.8% (95% confidence interval [CI], 4.9-20.8) and 6.6% (95% CI, 2.4-15.7) in those who received modified-dose anticoagulation (Fine-Gray hazard ratio, 2.18; 95% CI, 1.21-3.93). The cumulative incidence of recurrent VTE at 60 days in patients who initially received full-dose anticoagulation was 5.6% (95% CI, 0.2-11) and 0% in patients who received modified-dose anticoagulation. In conclusion, modified-dose anticoagulation appears to be a safe alternative to therapeutic anticoagulation in patients with cancer who develop deep vein thrombosis in the setting of thrombocytopenia.
format Online
Article
Text
id pubmed-8714719
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-87147192021-12-29 Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study Carney, Brian J. Wang, Tzu-Fei Ren, Siyang George, Gemlyn Al Homssi, Amer Gaddh, Manila Connolly, Gregory C. Shah, Vinay I. Bogue, Thomas Bartosic, Abigail Neuberg, Donna Baumann Kreuziger, Lisa Zwicker, Jeffrey I. Blood Adv Thrombosis and Hemostasis Venous thromboembolism (VTE) with concurrent thrombocytopenia is frequently encountered in patients with cancer. Therapeutic anticoagulation in the setting of thrombocytopenia is associated with a high risk of hemorrhage. Retrospective analyses suggest the utility of modified-dose anticoagulation in this population. To assess the incidence of hemorrhage or thrombosis according to anticoagulation strategy, we performed a prospective, multicenter, observational study. Patients with active malignancy, acute VTE, and concurrent thrombocytopenia (platelet count <100 000/µL) were enrolled. The cumulative incidences of hemorrhage or recurrent VTE were determined considering death as a competing risk. Primary outcomes were centrally adjudicated and comparisons made according to initial treatment with full-dose or modified-dose anticoagulation. A total of 121 patients were enrolled at 6 hospitals. Seventy-five patients were initially treated with full-dose anticoagulation (62%) and 33 (27%) with modified-dose anticoagulation; 13 (11%) patients received no anticoagulation. Most patients who received modified-dose anticoagulation had a hematologic malignancy (31 of 33 [94%]) and an acute deep vein thrombosis (28 of 33 [85%]). In patients who initially received full-dose anticoagulation, the cumulative incidence of major hemorrhage at 60 days was 12.8% (95% confidence interval [CI], 4.9-20.8) and 6.6% (95% CI, 2.4-15.7) in those who received modified-dose anticoagulation (Fine-Gray hazard ratio, 2.18; 95% CI, 1.21-3.93). The cumulative incidence of recurrent VTE at 60 days in patients who initially received full-dose anticoagulation was 5.6% (95% CI, 0.2-11) and 0% in patients who received modified-dose anticoagulation. In conclusion, modified-dose anticoagulation appears to be a safe alternative to therapeutic anticoagulation in patients with cancer who develop deep vein thrombosis in the setting of thrombocytopenia. American Society of Hematology 2021-12-20 /pmc/articles/PMC8714719/ /pubmed/34662892 http://dx.doi.org/10.1182/bloodadvances.2021005966 Text en © 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
spellingShingle Thrombosis and Hemostasis
Carney, Brian J.
Wang, Tzu-Fei
Ren, Siyang
George, Gemlyn
Al Homssi, Amer
Gaddh, Manila
Connolly, Gregory C.
Shah, Vinay I.
Bogue, Thomas
Bartosic, Abigail
Neuberg, Donna
Baumann Kreuziger, Lisa
Zwicker, Jeffrey I.
Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study
title Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study
title_full Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study
title_fullStr Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study
title_full_unstemmed Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study
title_short Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study
title_sort anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study
topic Thrombosis and Hemostasis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714719/
https://www.ncbi.nlm.nih.gov/pubmed/34662892
http://dx.doi.org/10.1182/bloodadvances.2021005966
work_keys_str_mv AT carneybrianj anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy
AT wangtzufei anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy
AT rensiyang anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy
AT georgegemlyn anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy
AT alhomssiamer anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy
AT gaddhmanila anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy
AT connollygregoryc anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy
AT shahvinayi anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy
AT boguethomas anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy
AT bartosicabigail anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy
AT neubergdonna anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy
AT baumannkreuzigerlisa anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy
AT zwickerjeffreyi anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy
AT anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy